We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+17.58%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$2.97B
AUM Growth
+$703M
Cap. Flow
+$803M
Cap. Flow %
27.04%
Top 10 Hldgs %
34.36%
Holding
350
New
119
Increased
64
Reduced
60
Closed
59

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$25.3M
2
LLY icon
Eli Lilly
LLY
+$24.5M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$18.4M
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$15.7M
5
MGNX icon
MacroGenics
MGNX
+$12.2M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$21.4M
2
KALV
KalVista Pharmaceuticals
KALV
+$20.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$17.9M
4
CLDX icon
Celldex Therapeutics
CLDX
+$17.7M
5
PRTA icon
Prothena Corp
PRTA
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 22.2%
2 Industrials 0.08%
3 Consumer Staples 0.05%
4 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARWR icon
301
PUT
Arrowhead Research
ARWR
$11.9B
– –
-200,000
Closed -$15.3M
AVDL
302
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-54,694
Closed -$366K
BFLY icon
303
Butterfly Network
BFLY
$1.89B
– –
-62,796
Closed -$1.24M
BIIB icon
304
PUT
Biogen
BIIB
$30B
– –
-360,000
Closed -$88.1M
BMY icon
305
Bristol-Myers Squibb
BMY
$133B
– –
-288,400
Closed -$17.9M
BNTX icon
306
PUT
BioNTech
BNTX
$22.9B
– –
-319,900
Closed -$26.1M
CMPS
307
CALL
Compass Pathways
CMPS
$1.53B
– –
-187,800
Closed -$8.95M
CYRX icon
308
CALL
CryoPort
CYRX
$761M
– –
-250,000
Closed -$11M
CYRX icon
309
PUT
CryoPort
CYRX
$761M
– –
-50,000
Closed -$2.19M
CYTK icon
310
CALL
Cytokinetics
CYTK
$10.5B
– –
-150,000
Closed -$3.12M
ETNB
311
DELISTED
89bio
ETNB
– –
-32,799
Closed -$799K
FATE icon
312
CALL
Fate Therapeutics
FATE
$286M
– –
-38,500
Closed -$3.5M
KYNB
313
CALL
Kyntra Bio
KYNB
$27.2M
– –
-12,000
Closed -$11.1M
HROW icon
314
Harrow
HROW
$1.45B
– –
-308,607
Closed -$2.12M
IMVT icon
315
Immunovant
IMVT
$7.93B
– –
-235,587
Closed -$6.21M
KALA icon
316
KALA BIO
KALA
$14.1M
– –
-35
Closed -$594K
KALV
317
CALL
DELISTED
KalVista Pharmaceuticals
KALV
– –
-145,500
Closed -$2.76M
LLY icon
318
CALL
Eli Lilly
LLY
$1.02T
– –
-100,000
Closed -$16.9M
MRNA icon
319
Moderna
MRNA
$21.8B
– –
-62,059
Closed -$8.99M
MRSN
320
DELISTED
Mersana Therapeutics
MRSN
– –
-4,240
Closed -$2.06M
NBIX icon
321
CALL
Neurocrine Biosciences
NBIX
$16.8B
– –
-23,700
Closed -$2.27M
NKTR icon
322
CALL
Nektar Therapeutics
NKTR
$2.39B
– –
-10,000
Closed -$2.55M
PBYI icon
323
CALL
Puma Biotechnology
PBYI
$404M
– –
-100,000
Closed -$1.03M
PRAX icon
324
Praxis Precision Medicines
PRAX
$8.58B
– –
-333
Closed -$275K
QDEL icon
325
CALL
QuidelOrtho
QDEL
$1.14B
– –
-25,300
Closed -$4.54M
10 11 12
13
14

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Ikarian Capital held 350 positions worth $2.97B, up 31% from $2.27B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Ikarian Capital deployed $803M of net new capital in Q1 2021, opening 119 new positions and adding to 64 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.

By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 24% a quarter earlier, followed by Industrials and Consumer Staples.

On the sell side, the largest reduction was Morphic Holding, Inc. Common Stock, an estimated $21.4M trimmed.

  • Ikarian Capital's largest Q1 2021 buy was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.
  • Ikarian Capital added most to X4 Pharmaceuticals in Q1 2021, an estimated $15.7M increase.
  • Ikarian Capital's biggest Q1 2021 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $21.4M.
  • Ikarian Capital fully exited Bristol-Myers Squibb in Q1 2021, selling an estimated $17.9M.
  • Ikarian Capital's ten largest holdings make up 34% of its $2.97B portfolio in Q1 2021.
  • Ikarian Capital opened 119 new positions and closed 59 in Q1 2021.
  • Ikarian Capital's portfolio value rose 31% quarter-over-quarter to $2.97B.

Based on Ikarian Capital's 13F filing for Q1 2021, filed 17 May 2021.